Brokerages Set Retrophin, Inc. (RTRX) PT at $36.50
Shares of Retrophin, Inc. (NASDAQ:RTRX) have been given an average recommendation of “Buy” by the seven analysts that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $36.50.
RTRX has been the topic of a number of recent research reports. BidaskClub upgraded Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a report on Friday, August 4th.
COPYRIGHT VIOLATION WARNING: “Brokerages Set Retrophin, Inc. (RTRX) PT at $36.50” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/brokerages-set-retrophin-inc-rtrx-pt-at-36-50/1608540.html.
Shares of Retrophin (NASDAQ:RTRX) traded up 0.12% during midday trading on Friday, hitting $24.54. The stock had a trading volume of 183,419 shares. Retrophin has a 52 week low of $15.55 and a 52 week high of $25.44. The firm’s market cap is $941.97 million. The company’s 50 day moving average is $23.87 and its 200 day moving average is $19.98.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.10). Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The firm had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. During the same period last year, the business posted $0.07 EPS. The company’s revenue was up 16.5% on a year-over-year basis. On average, equities analysts predict that Retrophin will post ($1.13) earnings per share for the current fiscal year.
In other news, COO Neil F. Mcfarlane sold 1,378 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the transaction, the chief operating officer now owns 13,622 shares in the company, valued at $306,495. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.41% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of RTRX. Nationwide Fund Advisors lifted its holdings in shares of Retrophin by 129.9% in the first quarter. Nationwide Fund Advisors now owns 51,841 shares of the biopharmaceutical company’s stock valued at $957,000 after purchasing an additional 29,290 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Retrophin by 12.8% during the first quarter. Wells Fargo & Company MN now owns 50,785 shares of the biopharmaceutical company’s stock worth $938,000 after acquiring an additional 5,763 shares during the period. JPMorgan Chase & Co. lifted its holdings in Retrophin by 14,062.4% during the first quarter. JPMorgan Chase & Co. now owns 131,852 shares of the biopharmaceutical company’s stock worth $2,434,000 after acquiring an additional 130,921 shares during the period. American International Group Inc. lifted its holdings in Retrophin by 7.1% during the first quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock worth $412,000 after acquiring an additional 1,475 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Retrophin during the first quarter worth $219,000.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.